Precision tools for modifying DNA sequences in living cells. CRISPR-Cas9 achieved the first approved therapy (Casgevy); next-generation approaches like base editing and prime editing offer even greater precision without double-strand breaks.
From a single lupus patient in Erlangen to pediatric trials in Rome, allogeneic programs at Allogene, and dual-targeted CD19/CD70 designs — CAR-T cell therapy is rewriting autoimmune medicine. We map the landscape: which diseases, which constructs, and who's winning the race to scale.
Apr 16, 2026 · 14 min read
The American College of Cardiology publishes its 2026 scientific statement on gene editing therapy for cardiovascular disease, covering CRISPR-based approaches to PCSK9, TTR amyloidosis, and hypertrophic cardiomyopathy. A formal signal that cardiology's regulatory framework is catching up to the science.
Apr 14, 2026 · 7 min read
Intellia places its CRISPR gene editing therapy nex-z on partial clinical hold following a serious liver adverse event, raising questions about in vivo LNP-delivered editing safety at scale. Over 450 patients had been dosed across MAGNITUDE trials.
Apr 14, 2026 · 7 min read
The first CRISPR-based therapy, Casgevy for sickle cell disease and beta-thalassemia, is now approved in the US, EU, UK, Canada, and six additional countries. Real-world data confirms durable transfusion independence.
Apr 2, 2026 · 6 min read
The longest-surviving pig-to-human kidney transplant patient crosses the 12-month milestone with stable graft function, powered by 69 genetic edits that removed pig antigens and added human immune genes.
Mar 28, 2026 · 7 min read
Predicts single-chain and multimer protein 3D structures from amino acid sequence using MSA-based deep learning. Set the modern benchmark on CASP14.
Wraps AlphaFold2 with MMseqs2-based MSA generation, making AF2 runs 40-60x faster. Accessible via Google Colab or local install.
Joint structure prediction of proteins, DNA, RNA, small molecules, ions, and covalent modifications in a single diffusion-based model.
Diffusion-based generative model that treats docking as a generative problem over ligand poses. No pre-specified binding pocket needed.
AutoDock Vina-based docking engine augmented with a 3D CNN scoring function. Uses Vina for sampling, CNN for scoring and re-ranking.
Classical rigid receptor, flexible ligand docking using empirical and knowledge-based scoring. The most widely used open-source docking tool.